Daily Cardiology Research Analysis
Analyzed 172 papers and selected 3 impactful papers.
Summary
Analyzed 172 papers and selected 3 impactful articles.
Selected Articles
1. Cardiovascular-Kidney-Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study.
In 5,646 older adults from ARIC, higher AHA CKM stages were incrementally associated with adverse LV remodeling and worse systolic/diastolic function, and with greater progression of remodeling. Over a median 9.0 years, incident HF rose steeply with stage: adjusted HR 3.6 for stage 3 and 8.3 for stage 4 versus stage 2.
Impact: This provides prospective, echocardiography-based validation that the CKM staging framework stratifies HF risk and myocardial remodeling in community-dwelling older adults.
Clinical Implications: Incorporate CKM staging into preventive cardiology for older adults to target aggressive risk factor modification (adiposity, metabolic risks, albuminuria) and early HF prevention strategies.
Key Findings
- CKM stage distribution: stage 3 (56.0%) and stage 4a (32.3%) were most common; stages 0–1 were rare (2.2% combined).
- Higher CKM stages were incrementally associated with adverse LV remodeling and worse systolic/diastolic function at baseline.
- Progression of adverse remodeling from visit 5 to 7 was greater with higher CKM stages.
- Incident HF increased with stage: adjusted HR 3.6 (95% CI 2.1–6.0) for stage 3 and 8.3 (95% CI 4.9–14.2) for stage 4 versus stage 2.
Methodological Strengths
- Community-based cohort with standardized echocardiography
- Longitudinal follow-up with incident HF adjudication and multivariable adjustment
Limitations
- Observational design limits causal inference
- Older population (66–90 years) may limit generalizability to younger cohorts; no events in stage 0–1 constrained reference choice
Future Directions: Validate CKM staging in diverse, younger, and intervention cohorts; test whether CKM stage–guided prevention reduces HF incidence.
BACKGROUND: Suboptimal cardiovascular-kidney-metabolic (CKM) health is highly prevalent in the United States, especially among older adults, but whether the CKM syndrome staging framework is predictive of incident heart failure (HF) in this population remains uncertain. METHODS: Participants from the ARIC Study (Atherosclerosis Risk in Communities; visit 5, 2011-2013) who underwent echocardiography were categorized according to the American Heart Association CKM syndrome staging framework, which is based on excess or dysfunctional adiposity, metabolic risk factors, kidney disease, subclinical cardiovascula
2. Chronic Kidney Disease Screening in Patients With Coronary Heart Disease: The Multinational INTERASPIRE Study.
Among 4,548 CAD patients, CKD (by KDIGO) was present in 32%. Critically, 51.3% of CKD cases would be missed if UACR were not measured alongside eGFR. Composite cardiovascular events at 1 year were highest in KDIGO high-risk groups, independent of other risk factors, yet cardio-renal protective therapy use was low.
Impact: Demonstrates that UACR is essential for CKD detection and risk stratification in CAD, with immediate implications for secondary prevention pathways globally.
Clinical Implications: Routine CKD screening in CAD clinics should include both eGFR and UACR; intensify uptake of cardio-renal protective therapies (e.g., RAAS inhibitors, SGLT2 inhibitors, finerenone where appropriate).
Key Findings
- CKD prevalence in CAD was 32% by KDIGO risk categories (low-moderate 19.7%, high 6.9%, very high 5.6%).
- Without UACR, 51.3% of CKD cases would have been undetected.
- Composite cardiovascular events at ~1 year occurred in 7.9%, highest in KDIGO high-risk groups (men 13.0%; women 11.8%), independent of other risk factors.
- Cardio-renal protective therapy utilization was low, revealing a major implementation gap.
Methodological Strengths
- Multinational cohort across all WHO regions with standardized kidney assessments
- Outcome follow-up with risk stratification by KDIGO and multivariable analyses
Limitations
- Observational design and short median follow-up (~1 year) limit causal inference and long-term prognostic assessment
- Complete kidney and therapy data available in subsets, introducing potential selection bias
Future Directions: Implement and evaluate integrated CKD screening (eGFR+UACR) within CAD pathways and test whether therapy intensification reduces cardio-renal events.
BACKGROUND: Chronic kidney disease (CKD) is an important risk factor for the progression of coronary artery disease (CAD). OBJECTIVES: The purposes of this study were to quantify the prevalence of CKD in CAD patients from 14 countries from all World Health Organization regions and to evaluate the prognostic value of estimated glomerular filtration rate (eGFR) and urinary albumin/creatinine ratio (UACR). METHODS: A total of 4,548 patients with CAD were included (79.6% were males; age range: 18-80 years). They were assessed for eGFR and UACR 6 to 24 months after the CAD diagnosis. Complete information on kidney function and cardio-renal protective therapy was available for 3,865 patients and follow-up data after a median of 1 year were available for 3,577 (92.5%). RESULTS: CKD according to the Kidney Disease Improving Global Outcomes classification was present in 32% of whom 19.7% were classified as low-moderate, 6.9% as high, and 5.6% as very high risk. Without UACR, 51.3% of them would have been undetected. The primary event, first of cardiovascular death, myocardial infarction, stroke, and hospitalization for heart failure, was observed in 7.9%, with the highest incidence in the Kidney Disease Improving Global Outcomes high-risk group (men: 13.0%; women: 11.8%). This relationship was independent of other risk factors and evident soon after the index examination. Only a minority of the patients received adequate cardio-renal protective therapy. CONCLUSIONS: Early screening for CKD in patients with CAD is important and should preferably include both eGFR and UACR to provide a complete diagnosis. Without UACR, half of those with CKD would remain undetected. Treatment with cardio-renal protective therapy was low, providing great potential for improvement.
3. Evaluation of recombinant human prourokinase for acute pulmonary embolism: A phase 2, randomized clinical trial.
In a phase 2, single-blind, multicenter RCT (n=107), both rhPro-UK (40 mg or 50 mg) and rt-PA produced similar 24-hour reductions in systolic pulmonary artery pressure with sustained improvements to day 30. Non-major bleeding events were numerically lower with rhPro-UK versus rt-PA (p=0.04), with two deaths overall (one per 40 mg rhPro-UK and rt-PA arms).
Impact: Introduces a potentially safer thrombolytic option for acute PE with comparable early hemodynamic efficacy to rt-PA. Findings support advancement to phase 3 evaluation.
Clinical Implications: If confirmed in phase 3, rhPro-UK could expand thrombolysis choices for high or intermediate-high risk PE, potentially reducing non-major bleeding while preserving efficacy. For now, it informs patient selection and risk–benefit discussions in centers with access to rhPro-UK.
Key Findings
- All arms achieved 24-hour sPAP reductions: rhPro-UK 40 mg −13.40 mmHg (95% CI −24.10 to −2.71), rhPro-UK 50 mg −15.42 mmHg (95% CI −25.93 to −4.91), rt-PA −16.02 mmHg (95% CI −25.53 to −6.51).
- Improvements in hemodynamic parameters were sustained through 30 days across groups.
- Non-major bleeding was numerically lower with rhPro-UK (40 mg: 63.9%; 50 mg: 55.6%) vs rt-PA (82.9%; p=0.04).
- Two deaths occurred (one in the 40 mg rhPro-UK group and one in the rt-PA group).
Methodological Strengths
- Randomized, multicenter, active-controlled design with prespecified hemodynamic endpoints.
- Direct comparator (rt-PA) enables clinically meaningful benchmarking.
Limitations
- Phase 2 sample size (n=107) limits precision and rare safety event detection.
- Single-blind design and short follow-up (7–30 days) may introduce bias and miss late events.
- Industry funding (Tasly Biopharmaceuticals) requires careful interpretation of safety signals.
Future Directions: Conduct adequately powered phase 3 double-blind trials to confirm efficacy/safety, optimize dosing, and evaluate clinically meaningful endpoints (mortality, recurrent PE, major bleeding) across risk strata.
BACKGROUND: Recombinant human prourokinase (rhPro-UK) is a novel plasminogen activator under investigation for acute pulmonary embolism (aPE). We aimed to explore the efficacy and safety of rhPro-UK vs. alteplase (recombinant tissue plasminogen activator [rt-PA]) in patients with aPE. METHODS: In this phase 2, randomized, single-blind, multicenter, active-controlled, randomized trial involved eighteen centers from university-affiliated tertiary hospitals across China. Patients aged 18-75 years with high or intermediate-to-high risk aPE were randomized to recei